Recent Updates in the Treatment of Follicular Lymphoma and Mantle Cell Lymphoma - Episode 5

Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL

, , , , ,

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Current Treatment Options in First-line FL
    EP. 2: ASH 2023 Updates on Frontline Therapies in FL
    EP. 3: Current Treatment Options in Second-line FL
    EP. 4: CAR T-cells as Third-line and Beyond Therapy for FL
    Now Viewing
    EP. 5: Bispecific T-cell Engagers as Third-line and Beyond Therapy for FL
    EP. 6: Tazemetostat as Third-line and Beyond Therapy for FL
    EP. 7: Zanubrutinib as Third-Line and Beyond Therapy for FL
    EP. 8: Choosing Bispecific T-cell Engager as Third-line and Beyond Therapy for FL
    EP. 9: Choosing CAR T-cells as Third-line and Beyond Therapy for FL
    EP. 10: Sequencing Immunotherapy in the Third-line and Beyond Setting for FL
    EP. 11: Unmet Needs in Treating Relapsed/Refractory FL
    EP. 12: Current Treatment Options in First-Line MCL
    EP. 13: ASH 2023 Updates on Frontline Therapies in MCL
    EP. 14: Current Treatment Options in Second-line MCL
    EP. 15: Current Treatment Options in Third-line MCL
    EP. 16: Sequencing Therapies in the Third-Line and Beyond Setting for MCL
    EP. 17: Future Directions and Unmet Needs in Relapsed/Refractory MCL
    x